540 related articles for article (PubMed ID: 25880207)
21. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.
Larsson LI
J Glaucoma; 2001 Apr; 10(2):109-14. PubMed ID: 11316092
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of the dorzolamide/timolol fixed combination versus latanoprost in the treatment of ocular hypertension or glaucoma: combined analysis of pooled data from two large randomized observer and patient-masked studies.
Fechtner RD; McCarroll KA; Lines CR; Adamsons IA
J Ocul Pharmacol Ther; 2005 Jun; 21(3):242-9. PubMed ID: 15969642
[TBL] [Abstract][Full Text] [Related]
23. Once-Daily Netarsudil Versus Twice-Daily Timolol in Patients With Elevated Intraocular Pressure: The Randomized Phase 3 ROCKET-4 Study.
Khouri AS; Serle JB; Bacharach J; Usner DW; Lewis RA; Braswell P; Kopczynski CC; Heah T;
Am J Ophthalmol; 2019 Aug; 204():97-104. PubMed ID: 30862500
[TBL] [Abstract][Full Text] [Related]
24. Latanoprost: experience of 2-year treatment in Scandinavia.
Alm A; Widengård I
Acta Ophthalmol Scand; 2000 Feb; 78(1):71-6. PubMed ID: 10726794
[TBL] [Abstract][Full Text] [Related]
25. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group.
Camras CB
Ophthalmology; 1996 Jan; 103(1):138-47. PubMed ID: 8628544
[TBL] [Abstract][Full Text] [Related]
26. [A comparison between latanoprost and timolol in treatment of patients with primary open-angle glaucoma and ocular hypertension].
Peng D; Li S; Li M; Shao H; Sun X; Sheng Y; Yu K; Fu P; Guo W; Meng F; Xu C; Zhu Z
Zhonghua Yan Ke Za Zhi; 2000 Jul; 36(4):285-8. PubMed ID: 11853616
[TBL] [Abstract][Full Text] [Related]
27. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Invernizzi T; Bottoli A; Autelitano A
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2566-73. PubMed ID: 10937568
[TBL] [Abstract][Full Text] [Related]
28. Circadian intraocular pressure control with dorzolamide versus timolol maleate add-on treatments in primary open-angle glaucoma patients using latanoprost.
Tamer C; Oksüz H
Ophthalmic Res; 2007; 39(1):24-31. PubMed ID: 17164574
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
30. Latanoprost : an update of its use in glaucoma and ocular hypertension.
Perry CM; McGavin JK; Culy CR; Ibbotson T
Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
[TBL] [Abstract][Full Text] [Related]
31. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
32. Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2).
Serle JB; Katz LJ; McLaurin E; Heah T; Ramirez-Davis N; Usner DW; Novack GD; Kopczynski CC;
Am J Ophthalmol; 2018 Feb; 186():116-127. PubMed ID: 29199013
[TBL] [Abstract][Full Text] [Related]
33. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% t.i.d. in patients with open-angle glaucoma or ocular hypertension. a 6-month, randomized, multicenter study. German Latanoprost Study Group.
Diestelhorst M
Graefes Arch Clin Exp Ophthalmol; 2000 May; 238(5):433-9. PubMed ID: 10901475
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma: a preliminary study.
Aung T; Wong HT; Yip CC; Leong JY; Chan YH; Chew PT
Ophthalmology; 2000 Jun; 107(6):1178-83. PubMed ID: 10857840
[TBL] [Abstract][Full Text] [Related]
35. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost.
Stewart WC; Day DG; Sharpe ED; Dubiner HB; Holmes KT; Stewart JA
Am J Ophthalmol; 1999 Dec; 128(6):692-6. PubMed ID: 10612504
[TBL] [Abstract][Full Text] [Related]
37. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.
Watson P; Stjernschantz J
Ophthalmology; 1996 Jan; 103(1):126-37. PubMed ID: 8628543
[TBL] [Abstract][Full Text] [Related]
38. Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma.
Chew PT; Aung T; Aquino MV; Rojanapongpun P;
Ophthalmology; 2004 Mar; 111(3):427-34. PubMed ID: 15019314
[TBL] [Abstract][Full Text] [Related]
39. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallel-group comparison trials.
Simmons ST; Dirks MS; Noecker RJ
Adv Ther; 2004; 21(4):247-62. PubMed ID: 15605619
[TBL] [Abstract][Full Text] [Related]
40. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components.
Diestelhorst M; Larsson LI;
Ophthalmology; 2006 Jan; 113(1):70-6. PubMed ID: 16263174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
